Navigation Links
Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth

Exposure to carcinogens in traffic emissions at particular lifetime points may increase the risk of developing breast cancer in women who are lifetime nonsmokers, a study by epidemiologists and geographers at the University at Buffalo has found.

Their study was conducted among women who lived in Erie and Niagara counties of New York State between 1996 and 2001. They found that higher exposure around the time of first menstruation to polycyclic aromatic hydrocarbons (PAHs), potential carcinogens found in traffic emissions, was associated with increased risk of premenopausal breast cancer.

However, for postmenopausal women, higher exposure to PAHs at the time of the first birth was associated with increased risk. Neither association was found in women with a history of smoking.

Results of the study were presented earlier this month at the annual meeting of the American Association for Cancer Research held in Anaheim, Calif. Jing Nie, Ph.D., a postdoctoral fellow in epidemiology in UB's School of Public Health and Health Professions is first author on the study.

"There is growing evidence that there may be times in a woman's life when exposures to potential carcinogens may be critical for breast-cancer initiation and development," said Nie. "Our study findings support the hypothesis that exposures in early life contribute to breast-cancer risk."

The study was based on data from the Western New York Exposures and Breast Cancer (WEB) study. All participants were women between the ages of 35 and 79 who lived in Erie or Niagara counties at the time of data collection. Women with primary, histologically confirmed breast cancer served as cases. Controls were randomly selected and matched to cases on age, race and county of residence.

Researchers in the WEB study conducted in-depth personal interviews with study participants to collect data on potential breast-cancer risk factors and a history of where they had lived at different times in their lives. Researchers were interested particularly in information related to four time periods: menarche (first menstrual period), first birth, 20 years prior to the interview and 10 years prior.

Several information sources provided data on traffic volumes on roads in question for the years from 1960 to 2002 and tail-pipe emissions, including measurements from tunnels and tests on individual vehicles. A geographic model was used to reconstruct historic traffic PAHs, using measurements of benzo[a]pyrene, a known potent mutagen and carcinogen, as a surrogate for total PAH exposure. Cruise emissions, cold engine emissions and intersection emissions were used to estimate total traffic PAH emissions.

In addition, meteorological information was used in a geographic dispersion model to determine PAH exposure at each participant's residence.

While the researchers found increased risk for exposure at menarche and first birth for premenopausal and postmenopausal participants, respectively, who were lifetime nonsmokers, there was no association of traffic emissions with breast cancer for the other time periods.

Nie said these findings related to PAHs need to be interpreted with caution, because they could be explained by other compounds in vehicle exhaust or by other exposures related to the traffic emissions.

"While these results are subject to the limitations of epidemiologic observational studies, they are provocative in providing evidence both of the importance of early exposures and of the potential importance of an environmental agent in risk of breast cancer," said Nie. "Further examination of PAH exposure in early life is clearly warranted."

The UB researchers currently are examining whether genetic polymorphisms involving PAH metabolism may modify the risk, if lifeline cumulative exposure may be associated with the risk and if this study may be replicated in another geographic settings.

Jo Freudenhei m, Ph.D., UB professor of social and preventive medicine, heads the WEB study.

Additional researchers were Jan Beyea, Ph.D., from Consulting in the Public Interest of Lambertville, N.J., who developed the geographic dispersion model; Matthew Bonner, Ph.D., of the National Cancer Institute (NCI); Daikwon Han, Ph.D., Dominica Vito, and Maurizio Trevisan, M.D., from the Department of Social and Preventive Medicine, UB School of Public Health and Health Professions; and Peter Rogerson, Ph.D., of the Department of Geography, UB College of Arts and Sciences, along with John Vena, Ph.D., now at the University of South Carolina, and Paola Muti, M.D., now at Italy's National Cancer Institute in Genoa.

The research was supported in part by grants from the U.S. Army Breast Cancer Research Program and NCI.

The University at Buffalo is a premier research-intensive public university, the largest and most comprehensive campus in the State University of New York.


Source:University of Buffalo

Related biology news :

1. New SARS Protein Linked To Important Cell Doorway
2. Use of Insecticides Linked to Lasting Neurological Problems for Farmers
3. Nighttime Dying Linked To Sleep Apnea From Brain Cell Loss
4. Defective Gene Linked to Two Inherited Immune Deficiencies
5. Exposure to volcanic mineral associated with increased mesothelioma incidence in Turkey
6. Exposure to dioxins influences male reproductive system, study of Vietnam veterans concludes
7. Weill Cornell Research Reveals Secrets Of Trafficking Within Cells
8. Timing is everything: First step in protein building revealed
9. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
10. First atlas of key brain genes could speed research on cancer, neurological diseases
11. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
Post Your Comments:

(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
Breaking Biology Technology: